. TPK activity therefore represents an excellent biological target for the development of new cancer drugs (Dvir et al., 1991; Ennis et al., 1991) . New therapeutic strategies diected against growth factors might thus include tyrosine kinase inhibitors to interfere with signalling transduction cascades after growth factor is bound to its receptor (Harris et al., 1992) . In breast cancer, nearly all the known sources for TPK activity, including epidermal growth factor (EGF) receptors (EGFR) (Sainsbury et al., 1987) , insulin-like growth factor type 1 (IGF-1) receptors (IGF-lR) (Foekens et al., 1989) , HER-2 (Slamon et al., 1987) and c-src gene products (Ottenhoff-Kalff et al., 1992) are bound to the plasma membrane (Cantley et al., 1991; Fisher et al., 1991) . Inreased TPK activity has, however, been described in both membrane and cytosol fractions (Hennipman et al., 1989; Durocher & Chevaler, 1990; Lower et al., 1993) . The signifi of cytosolic TPK expression remains to be clarified.
The initial report of Sainsbury et al. (1987) suggested that amplcation of EGFR was a poor prognostic factor in node-negative breast cancer patients. However, the role of EGFR as a prognostic indicator for patients with breast cancer is currently a matter of extensive debate Spyratos et al., 1994) . There is aLso little agreement on the prognostic value of-HER-2 (SLamon et and IGF-IR (Foekens et al., 1989; Peyrat et al., 1990) . In contrast to selective detection of a single growth factor receptor or oncoprotein, overall measurement of TPK actmity expression might reflect integrated tumour aggressiveness (Dougall et al., 1993) . TPK activity might thus provide powerful prognostic information regarding women with breast cancer.
In this study, cytosolc TPK activity was measured m 249 patients with node-positive primary breast tumours, a subset of patients which has been previously evaluated for steroid receptors and urokinase-type plainogen activator (UPA) Processing and pathological examination of tumours was performed as described previously (Foekens et al., 1989 , using reagents of a kit which is now commerially available (uPA Elisa kit A894, American Diagnostica, Greenwich, USA).
TPK enzyme activity was determined as previously described (Bolla et al., 1993) , using [32P1ATP as the phosphate donor and poly(glutamic acid-tyrosine) 
Res
Association between TPK and patient and twnour characteristics Cytosolic TPK activity varied from 0 to 35.9 pmol ATP min-1mg-I proten (median 11.4; mean + s.d. 12.1 ± 6.8).
No correlation was found with tumour size, number of positive lymph nodes or differentiation grade (Table II) . TPK levels were negatively associated with age and menopausal status of the patients. In addition, higher concentrations of TPK were found in ER-negative and PR-negative tumours as compared with receptor-positive tumours. Finally, a positive correlation was found between TPK and UPA.
Associations of TPK and otherfactors with (disease-free) survival DFS, disease-free survival; OS, overall survival; P, P-vahie; NS, not significant. aonly n = 2. bIThe combined group of the three other phenotypes with one or both receptors negative.
for actuarial disease-free ( Figure la ) and overall survival (Figure lb) show the increased hazard rates of our patients with TPK-positive primary tumours.
Cox multivariate analysis of TPK status
The independent predictive value of TPK on the rate of relapse and death was with Cox multivariate analysis including various clinical and histological parameters (age, menopausal status, tumour size, number of positive lymph nodes), ER-PR status and UPA (Table IV) . Two hundred and thirty-seven patients with complete data were analysed. For disease-free survival, the dominant factors selected in the standar model were tumour size and the number of positive lymph nodes. For overall survival, relevant variables were the number of positive lymph nodes, ER-PR status and tumour size. For both analyses, UPA status (+ vs -) and TPK status (high vs low) significantly added to the model with relative relapse rates of 2.18 and 1.74 and relative death rates of 1.71 and 1.58, as shown by Kaplan-Meier curves for disease-free ( Figure 2a ) and overall survival (Figure 2b ). Addition of adjuvant chemotherapy as an indicator variable to the multivariate models did not affect the estimates of the regression coefficients of the cytosolic parameters and was therefore not included in the models presented in Table IV .
Several growth factor receptors and oncoproteins, including EGFR (Sainsbury et al., 1987) , IGF-1R (Foekens et al., 1989; Peyrat et al., 1990 ) and HER-2 (Slamon et al., 1987) , have been reported in breast tumours. At present, however, there is little agreement on some clinical relationship and their prognostic value . Lack of a standardised assay is probably one of the most important reasons for the variability observed (Koenders et al., 1992; Spyratos et al., 1994) . In addition, a single growth factor receptor or oncoprotein probably cannot reliably account for all the cellular signals that occur during tumour growth, invasion and metastasis (Dougall et al., 1993) . TPK activity has been associated with the cytoplasmic domain of many growth factor receptors as well as oncogene products (Cantley et al., 1991; Fisher et al., 1991) . TPK measurement might thus result in more accurate prediction of patient clinical behaviour than selective measurement of these proteins. In this study, cytosolic TPK activity was assessed in tumours from 249 node-positive primary breast cancer patients. Although TPK has been associated with membranebound protiens (Cantley et al., 1991; Fisher et al., 1991) , measurement of TPK activity in cytosol better separates normal breast tissues, benign breast diseases and breast cancers than membrane-bound TPK activity (Hennipman et al., 1989; Lower et al., 1993) . Moreover, assay of cytosols appears to be more appropriate for rouine use. Measurements were thus performed in cytosols routinely prepared for steroid receptor measurement. We determined TPK enzyme activity using [V2PATP and a polypeptide artificial substrate (Bolla et al., 1993 ). An enzyme-linked immunosorbent assay (ELISA) has been recently described for TPK measurement (Schraag et al., 1993) . At present, little is known about the correlation between the activity data obtained with enzyme activity assay and antigen measurement by ELISA.
The levels of TPK in our study are in agreement with previously published data using the same assay (Bolla et al., 1993 Durocher & Chevalier, 1990; Bolla et al., 1993; Lower et al., 1993) . This relationship is similar to that described for EGFR (Foekens et al., 1989; and HER-2 . However, TPK activity has been associated with many growth factor receptors and oncoproteins. Moreover, at least 70% of the TPK activity in breast cancer cytosols originates from the presence of the c-src oncogene product (Ottenhoff-Kalif et al., 1992) , and the contribution of EGFR to TPK activity seems to be low (Durocher & Chevalier, 1990 (Laiho & Keski-ga, 1989; Neidbala & Sartorelli, 1989) . High levels of TPK were associated with an increased risk of relapse and death. These data concerning disease-free survival are in agreement with the few previously published pilot studies, which included 18 patients (Hennipman et al., 1989) , 86 patients (Lower & Williams, 1992) and 40 nodenegative and 40 node-positive patients (Bolla et al., 1993 ). TPK retained its prognostic importance in Cox multivariate analysis, including classical clinical and histological factors, steroid receptors and UPA. However, the protease expression, which has been related mainly to invasion and metastasis, appeared as a stronger prognostic factor. ER and PR were stronger predictors of overall survival than of diseasefree survival, probably because of the better response to palliative hormonotherapy of ER-positive patients (Nomura et al., 1992) . In contrast, disease-free survival and overall survival were equally affected by TPK. The relationship between TPK and sensitivity to adjuvant therapy needs to be clarified. In this study, it could not accurately be assessed because adjuvant therapy was predominantly given to premenopausal patients. Interestingly, however, addition of adjuvant therapy to the multivariate model did not affect the estimates of the cytosolic parameters, including that of TPK.
Assessment of TPK could be helpful for the identification of patients at high risk of recurrence, and thus for the selection of patients for adjuvant therapy. However, the prognostic value of TPK must be confirmed in prospective studies. Measurement of TPK activity might in addition become important in predicting response to TPK inhibitors, of which many are likely to be tested in clinical trials in the near future.
